The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1036
September 25, 1998
View Complete Issue         Table of Contents 2019 
Brinzolamide--A New Topical Carbonic Anhydrase Inhibitor for Glaucoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Brinzolamide--A New Topical Carbonic Anhydrase Inhibitor for Glaucoma
September 25, 1998 (Issue: 1036)
Brinzolamide (Azopt - Alcon), a thieno-thiazine-6-sulfonamide carbonic anhydrase inhibitor, has been approved by the FDA in a 1% ophthalmic suspension for treatment of elevated intraocular pressure due to ocular hypertension or open-angle glaucoma....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Brinzolamide--A New Topical Carbonic Anhydrase Inhibitor for Glaucoma
Article code: 1036c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.